Wui-Jin Koh named chief medical officer at NCCN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Wui-Jin Koh was named to the newly created position of senior vice president and chief medical officer of the National Comprehensive Cancer Network.

Koh is a board-certified radiation oncologist, professor, and medical director for radiation oncology at Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance, an NCCN Member Institution. He specializes in the treatment of gynecologic and gastrointestinal malignancies.

The new CMO role will include overseeing the NCCN Oncology Research Program, which emphasizes collaborative research.

Koh will also help oversee the flagship NCCN Clinical Practice Guidelines in Oncology Guide program. In addition, he will be responsible for medical leadership and oversight for NCCN’s continuing medical education program, and will represent the organization at clinical and scientific meetings.

Koh began contributing his time to NCCN as a founding member of the NCCN Guidelines Panel for Uterine/Cervical Cancer in 1997. He was named panel co-chair in 2004.

His work is an integral part of the ongoing creation of the NCCN Harmonized Guidelines for Sub-Saharan Africa. Koh also served as a member of the pancreatic cancer panel for seven years, and currently sits on the editorial board of the Journal of the National Comprehensive Cancer Network. He is also an editorial board member for Cancer, American Journal of Clinical Oncology, and Gynecologic Oncology Research and Practice, and a former member for Gynecologic Oncology.

Outside of NCCN, Koh has held leadership positions with NRG Oncology (formerly Gynecologic Oncology Group), Western Association of Gynecologic Oncologists, International Society of Gynecologic Cancer, the National Cancer Institute’s Gynecologic Cancer Steering Committee, and the Society of Gynecologic Oncology.

Koh’s official start date will be Oct. 1.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login